Navigation Links
Arpida Announces Full Year 2007 Financial Results
Date:3/13/2008

REINACH, Switzerland, March 13 /PRNewswire-FirstCall/ -- Arpida Ltd (SWX: ARPN) announced today its financial results for the year ending 31 December 2007.

2007 highlights

Major pipeline progress:

- Second pivotal Phase III trial with intravenous iclaprim in cSSSI achieves its pre-specified primary endpoint, as did the first

- Submission of New Drug Application (NDA) for intravenous iclaprim in cSSSI initiated

- First patients enrolled in a Phase II trial with intravenous iclaprim in HAP/VAP/HCAP, an important potential second indication
- Progress of Phase I programme with oral iclaprim

- Promising results of 'first-in-man' studies with AR-709

- Novel antibiotic AR-2474 achieves preclinical proof of concept

- Raised CHF 51.9 million in a secondary offering in March 2007 - Late-stage antifungal therapy added to pipeline via acquisition of TLT Medical Ltd.
- Extensive presence at scientific conferences

- Cash and financial investments of CHF 68.1 million at 31 December 2007

Post-Year-End Events

- Oral iclaprim moves into Phase II efficacy trial in cSSSI

2008 Outlook - Completion of patient enrolment in Phase II trial with oral iclaprim in cSSSI

- Completion of patient enrolment in Phase II trial with intravenous iclaprim in

HAP/VAP/HCAP

- Completion of patient enrolment in Phase III trial with TLT in onychomycosis

- Regulatory review of NDA for intravenous iclaprim in cSSSI in USA

- Submission of application for marketing authorisation in EU

Dr Khalid Islam, President and CEO, commented: "We're tremendously proud of the progress we've achieved in the year under review. By early 2008, we have one product candidate in an NDA filing process, one product in a Phase III, and two additional Phase II development programs. We are expecting the filing of the NDA for intravenous iclaprim in cSSSI to be completed shortly. Mark
'/>"/>

SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
2. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
3. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
4. Arpida-Supported CME Symposium Available Online
5. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
6. Arpida Presents Preclinical Data on AR-2474 at ICAAC
7. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
8. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
9. Arpida Interim Results for six Months to 30 June 2007
10. Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
11. WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Gene synthesis and bioengineering company ... into a technology access and services agreement with ... proprietary protein engineering technology, known as “ProteinGPS®” to ... extremely excited that the global leader ADM has ... bioengineering technology has now been validated through many ...
(Date:12/17/2014)... Md. , Dec. 17, 2014 CASI ... company dedicated to the acquisition, development and commercialization of ... for the global market with a primary commercial focus ... it has been granted a Type C meeting with ... the meeting will be held in February 2015.  During ...
(Date:12/15/2014)... Israel , Dec. 15, 2014 /PRNewswire/ ... a leading developer of adult stem cell technologies for ... Therapeutics Ltd. was awarded a grant of approximately $1.1 ... the Chief Scientist (OCS).  This is the eighth year ... from the Office of the Chief Scientist, which is ...
(Date:12/15/2014)... COPENHAGEN, Denmark , Dec. 15, 2014 /PRNewswire/ ... its innovative TransCon technology to address significant unmet ... from its ongoing Phase 2 pediatric study to ... growth hormone deficiency, or GHD.  This interim analysis ... the anticipated total enrollment in the study, completing ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4
... the Annual Report to the Nation on the Status ... deaths for many types of cancers. This encouraging news can ... smoking and improved diet, and early detection. ... the blood cancers, early detection is rare, there are no ...
... Neb., April 1, 2011 Transgenomic, Inc. ... have completed studies employing the company,s high-sensitivity cancer ... and BLOCker™-Sequencing.  Results from these studies will be ... (AACR) meeting in Orlando, Florida, April 2-6, 2011. ...
... NY As part of the quest to form ... electronic, and medical devices, researchers at the U.S. Department ... molecules in thin films remain frozen at a temperature ... have a range of applications extending from organic solar ...
Cached Biology Technology:The Leukemia & Lymphoma Society: Accelerating Cures Must Be a Priority 2Transgenomic, Inc. Presentations to Describe High-Sensitivity Detection of Cancer Biomarkers at the 2011 American Association for Cancer Research Meeting 2Transgenomic, Inc. Presentations to Describe High-Sensitivity Detection of Cancer Biomarkers at the 2011 American Association for Cancer Research Meeting 3Transgenomic, Inc. Presentations to Describe High-Sensitivity Detection of Cancer Biomarkers at the 2011 American Association for Cancer Research Meeting 4Expanding the degrees of surface freezing 2
(Date:12/5/2014)... VIEW, Calif. , Dec. 4, 2014 /PRNewswire/ ... safety has boosted investments in new testing and ... has also given rise to a range of ... by the requirements of Generation Y, which is ... technologies. As a result, product development strategies of ...
(Date:12/3/2014)... -- As part of our commitment to offering the ... announce the release of a new reader that will ... data that they need. The Atlas 2000 ... readers. Many such devices have serious shortcomings when it ... models force users to navigate numerous complicated steps in ...
(Date:11/21/2014)... Nov. 20, 2014 C-Labs LLC, a leading ... of Things (IoT), today announced the appointment of ... officer. Previously a strategic advisor to the firm, Mr. ... Mr. Traynor is based out of the C-Labs office ... to Chris Muench , Chief Executive Officer. ...
Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Inception Technologies to Release New Biometric Reader 2C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2
... been found to negatively affect these teenagers health in ... and cancers of the reproductive system. Given these findings, ... at increased risk for early puberty in order to ... youths., New research shows that greater support from mothers ...
... -- In response to the need for localized efforts ... threatened staghorn coral, Diego Lirman, Ph.D., and James Herlan, ... Marine and Atmospheric Science (RSMAS) have established an ... The goals of the coral nursery are to ...
... Inc.,(Pink Sheets: ESMT) ("e-Smart" or the "Company") responds ... in which a series of serious allegations,are made ... as untrue, inaccurate and misleading. IDsmart is operated ... plead guilty to,securities fraud charges in the U.S. ...
Cached Biology News:Family conditions may affect when girls experience puberty 2New south Florida nursery to focus on staghorn corals 2e-Smart Technologies Responds to Press Release Issued By IDsmart LLC 2e-Smart Technologies Responds to Press Release Issued By IDsmart LLC 3
Glutamate Receptor 5/1a...
... to Asparagine synthetase ( Abpromise ... Antigen: ... in the C-terminus of Human ... Entrez GeneID: 440 ...
Shh Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Anti-human C5/C5b, Clone 568, Monoclonal Antibody...
Biology Products: